TrovaGene Inc Share Price Nasdaq
Equities
US8972384080
Biotechnology & Medical Research
Sales 2024 * | 442K 35.2M | Sales 2025 * | - | Capitalization | 157M 12.54B |
---|---|---|---|---|---|
Net income 2024 * | -45M -3.59B | Net income 2025 * | -57M -4.54B | EV / Sales 2024 * | 356 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.59
x | P/E ratio 2025 * |
-3.32
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.29% |
Latest transcript on TrovaGene Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 03/03/13 |
James Levine
DFI | Director of Finance/CFO | 53 | 11/07/21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 10/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 21/04/20 |
Gary Pace
BRD | Director/Board Member | 76 | 21/04/20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 03/03/13 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |